Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma

• Type of Material: Article
• Authors: Ryan J Summers, Emory University; David T Teachey, University of Pennsylvania
• Language: English
• Date: 2023-10-01
• Publisher: Elsevier
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2022 Elsevier Inc. All rights reserved.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): https://doi.org/10.1016%2Fj.clml.2022.07.010
• Title of Journal or Parent Work: Clinical Lymphoma, Myeloma, & Leukemia
• Volume: 22
• Issue: 10
• Start Page: 718
• End Page: 725
• Grant/Funding Information: This work was funded in part by R01CA193776, R01CA264837, X01HD100702, and R03CA256550 and the Leukemia and Lymphoma Society (DTT)
• Keywords: small molecule inhibitors; acute lymphoblastic leukemia; proteasome inhibitors; chimeric antigen receptor T-cells; immunotherapy
• Research Categories: Health Sciences, Oncology; Biology, Cell; Health Sciences, Rehabilitation and Therapy

Abstract

While outcomes for children with T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL) have improved significantly with contemporary therapy, outcomes for patients with relapsed or refractory (r/r) disease remain dismal. Improved risk stratification and the incorporation of novel therapeutics have the potential to improve outcomes further in T-ALL/T-LL by limiting relapse risk and improving salvage rates for those with r/r disease. In this review we will discuss the challenges and new opportunities for improved risk stratification in T-ALL and T-LL. We will further discuss the recent incorporation of the novel therapeutics nelarabine and bortezomib into front-line therapy for children with T-ALL and T-LL. Finally, we will address new classes of targeted small molecule inhibitors, immunotherapeutics, and chimeric antigen receptor T-cell therapies under investigation in r/r T-ALL and T-LL.